CIPNIA-OS: An Instrument for Evaluating Oxaliplatin-Induced Peripheral Neuropathy

The chemotherapy-induced peripheral neuropathy integrated assessment–oxaliplatin subscale (CIPNIA-OS) tool was found to be a valid instrument for assessing oxaliplatin-induced peripheral neuropathy (OIPN), according to results of a study published in BMC Cancer.

Chemotherapy-induced peripheral neuropathy is a difficult condition to evaluate given its complicated underlying molecular mechanism and the subjective nature of symptoms.

To develop and assess a tool specifically for OIPN, this study was conducted by investigators in China between 2021 and 2022. The CIPNIA-OS instrument was developed through a literature search and expert panel consensus of items. The CIPNIA-OS was validated with a cohort of 186 patients, and outcomes were compared with the European Organization of Research and Treatment of Cancer Quality of Life Questionnaire-CIPN 20-item (QLQ-CIPN20) and National Cancer Institute-Common Toxicity Criteria Adverse Events (CTCAE) instruments.

The CIPNIA-OS comprised 20 items covering 7 factors.

The validation cohort comprised 55.91% women, median age 57.7 years, and 65.59% had a cumulative oxaliplatin dose of less than 750 mg/m².

The mean CIPNIA-OS score was 5.12 (range, 0 to 19) and the scores had internal consistency (α, 0.764) and stability (interclass correlation coefficient [ICC], 0.997).

Significant correlations were observed between CIPNIA-OS and QLQ-CIPN20 scores (r, 0.777; P <.01) and CTCAE scores (r, 0.661; P <.01). These correlations were stronger than the correlation observed between QLQ-CIPN20 and CTCAE scores (r, 0.417; P <.01).

Stratified by chemotherapy cycle, CIPNIA-OS and QLQ-CIPN20 scores were more similar during earlier cycles (P <.05).

The CIPNIA-OS instrument was only validated during chemotherapy receipt. Additional study is needed to assess its utility for long-term OIPN symptoms.

“The validation results supported that CIPNIA-OS had good reliability, stability, construct, criterion validity, and was more accurate and sensitive than QLQ-CIPN20 in the evaluation of OIPN,” concluded the study authors.

Reference

Gu Z, Chen C, Gu J, et al. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment – oxaliplatin subscale: a prospective cohort study. BMC Cancer. 2023;23(1):1109. doi:10.1186/s12885-023-11541-7